Putting an ear to the ground: Where now with Quinacrine?

International Journal of Gynecology and Obstetrics

Volumn 69, Issue 1, 2000, Pages 55-65

  Pine, R N ^a   Pollack, A E ^a  

^a AVSC International   (United States)

Author keywords

Neonate; Polyhydramnios; Pregnancy; Pseudohypoaldosteronism

Indexed keywords

MEPACRINE;

ARTICLE; CONTRACEPTION; FAMILY PLANNING; FEMALE; FEMALE STERILIZATION; HEALTH CARE POLICY; HEALTH HAZARD; HUMAN; MEDICAL ETHICS; PRIORITY JOURNAL; PUBLIC HEALTH; TECHNIQUE; TECHNOLOGY; TOXICOLOGY; WORLD HEALTH ORGANIZATION;

GENETICS AND REPRODUCTION;

ETHICS, MEDICAL; FEMALE; HUMANS; POLICY MAKING; QUINACRINE; STERILIZATION, REPRODUCTIVE; UNITED STATES; WOMEN'S HEALTH;

EID: 0034177524     PISSN: 00207292     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0020-7292(00)00189-2     Document Type: Article

References (89)

1. Zipper J.A., Stacchetti E., Medel M. Human fertility control by transvaginal application of quinacrine on the fallopian tube. Fertil Steril. 21(8):1970;581-589.
2. Zipper J., Stacchetti E., Medel M. Transvaginal chemical sterilization: clinical use of quinacrine plus potentiating adjuvants. Contraception. 12(1):1975;11-21.
3. Zipper J., Cole L.P., Goldsmith A., Wheeler R., Rivera M. Quinacrine hydrochloride pellets: preliminary data on a nonsurgical method of female sterilization. Int J Gynecol Obstet. 18(4):1980;275-279.
4. FHI's role in search for nonsurgical sterilization. Network. 14(4):1994;27.
5. Laufe L.E., Sokal D.C., Cole L.P., Shoupe D., Schenken R.S. Phase I prehysterectomy studies of the transcervical administration of quinacrine pellets. Contraception. 54:1996;181.
6. Sokal D.C., Zipper J., Guzman-Serani R., Aldrich T.E. Cancer risk among women sterilized with transcervical quinacrine hydrochloride pellets, 1997-1991. Fertil Steril. 64(2):1995;325-326.
7. Hieu D.T., Tan T.T., Tan D.N., Nguyet P.T., Than P., Vinh D.Q. 31,781 cases of non-surgical female sterilization with quinacrine pellets in Vietnam. Lancet. 342:1993;213-217.
8. Benagiano G. Sterilisation by quinacrine (Letter). Lancet. 344:1994;689.
9. Carignan C.S., Rogow D., Pollack A.E. The quinacrine method of nonsurgical sterilization: report of an experts meeting, AVSC Working Paper No. 6. 1994;10 AVSC International, New York.
10. Highlights of International Medical Advisory Panel (IMAP) meeting: use of quinacrine pellets for female sterilization not recommended. IPPF Med Bull. 27(6):1993;4.
11. Wilson E.W. The development of new technologies for female sterilization: conclusions and recommendations for research. Int J Gynecol Obstet. 51(Suppl 1):1995;S73-S74.
12. Wilson E.W. The development of new technologies for female sterilization: conclusions and recommendations for research. Int J Gynecol Obstet. 51(Suppl 1):1995;S74.
13. Carignan C.S., Rogow D., Pollack A.E. The quinacrine method of nonsurgical sterilization: report of an experts meeting, AVSC Working Paper No. 6. 1994;4 AVSC International, New York.
14. Carignan C.S., Rogow D., Pollack A.E. The quinacrine method of nonsurgical sterilization: report of an experts meeting, AVSC Working Paper No. 6. 1994;8-9 AVSC International, New York.
15. Pies C., Potts M., Young B. Quinacrine pellets: an examination of nonsurgical sterilization. Int Fam Plann Perspect. 20(4):1994;139-140.
16. Pollack A.E., Carignan C.S. The use of quinacrine pellets for non-surgical female sterilisation. Reprod Health Matters. 2:1993;121.
17. FHI Quinacrine studies. Network. 16(1):1995;27.
18. Sokal D.C., Zipper J., King T. Transcervical quinacrine sterilization: clinical experience. Int J Gynecol Obstet. 51(Suppl 1):1995;S63.
19. Saheli A. Quinacrine: the sordid story of chemical sterilisations of women. 1997: Contraception crisis (Editorial). The Times of India. March 18:1997;12.
20. Hartmann B., Visvanathan N. A risky business? Quinacrine, used to sterilize women worldwide, has yet to be proved safe. The Boston Globe. August 8:1997;D1-D3.
21. Mulay S. Quinacrine sterilisation: unethical trials. Econ Polit Wkly. 879:1997;1.
22. Plea to stop use of quinacrine for sterilising women. The Independent, 1997;February 24:4.
23. Shallet L. Business as usual for quinacrine sterilisation in Chile. Reprod Health Matters. 6:1995;145.
24. Visvanathan N., Rao M. Women at risk: quinacrine sterilisation, a practice that defies accepted international norms, continues in India. Frontline. 14(19):1997;94-95.
25. Kessel E. 100,000 quinacrine sterilizations. Adv Contracept. 12:1996;69-76.
26. Quinacrine sterilisation still being done despite expert advice against it. Reprod Health Matters 1997;9:176.
27. Freedman A.M. Population bomb: two Americans export chemical sterilization to the third world. Wall Street J. June 18:1998;A1.
28. Freedman A.M. Chile bans quinacrine sterilizations in latest setback to U.S. distributors. Wall Street J. July 10:1998;A4.
29. Freedman A.M. Swiss concern halts output of quinacrine. Wall Street J. June 26:1998;A2.
30. Karp J., Freedman A.M. India bans use of quinacrine for sterilizations. Wall Street J. August 18:1998;A17.
31. Freedman A.M. Researchers to stop distribution of drug for sterilization. Wall Street J. October 19:1998;C17.
32. Carignan C.S., Rogow D., Pollack A.E. The quinacrine method of nonsurgical sterilization: report of an experts meeting, AVSC Working Paper No. 6. 1994;1,10 AVSC International, New York.
33. Wilson E.W. The development of new technologies for female sterilization: conclusions and recommendations for research. Int J Gynecol Obstet. 51(Suppl 1):1995;S73.
34. Barnett B. Search for nonsurgical sterilization continues. Network. 18(1):1997;16.
35. Barnett B. Search for nonsurgical sterilization continues. Network. 18(1):1997;16-20.
36. Kessel E. Quinacrine sterilization: an assessment of risks for ectopic pregnancy, birth defects and cancer. Adv Contracept. 14:1998;81-90.
37. Laufe L.E., Sokal D.C., Cole L.P., Shoupe D., Schenken R.S. Phase I prehysterectomy studies of the transcervical administration of quinacrine pellets. Contraception. 54:1996;181-186.
38. Sokal D.C., Zipper J., Guzman-Serani R., Aldrich T.E. Cancer risk among women sterilized with transcervical quinacrine hydrochloride pellets, 1997-1991. Fertil Steril 1995. 64(2):1977;325-334.
39. Suhadi A., Anwar M., Soejoenoes A. Four-year clinical evaluation of Quinacrine pellets for non-surgical female sterilization. Adv Contracept. 14:1998;69-77.
40. Barnett B. Search for nonsurgical sterilization continues. Network. 18(1):1997;17.
41. Sokal D.C., Zipper J., Guzman-Serani R., Aldrich T.E. Cancer risk among women sterilized with transcervical quinacrine hydrochloride pellets, 1977-1991. Fertil Steril. 64(2):1995;333.
42. David C. Sokal, Associate Medical Director, Clinical Trials Division, Family Health International, personal communication, December 1999.
43. New quinacrine sterilisation 'trials' halted by international women's health movement protests. Reprod Health Matters 1999;7(14):177.
44. USP DI Volume I: Drug Information for the Health Care Professional Update Monographs. Per personal communication with Keith Johnson, Director, Division of Information Development, of 1/7/00, to be posted on Micromedex web site, available from http://www.micromedex.com/cust_center/uspdi/cs-uspv1.htm (print copy available from AVSC International).
45. Berer M. The quinacrine controversy continues. Reprod Health Matters. 6:1995;143.
46. Disease clustering: hide or seek? (Editorial). Lancet 1990;336:717-718.
47. Elwood M. Critical appraisal of epidemiological studies and clinical trials. 2nd:1998;34 Oxford University Press, New York.
48. Sokal D.C., Zipper J., Guzman-Serani R., Aldrich T.E. Cancer risk among women sterilized with transcervical quinacrine hydrochloride pellets, 1977-1991. Fertil Steril. 64(2):1995;331-333.
49. Berer M. The quinacrine controversy continues. Reprod Health Matters. 6:1995;142-144.
50. Sokal D.C., Zipper J., King T. Transcervical quinacrine sterilization: clinical experience. Int J Gynecol Obstet. 51(Suppl 1):1995;S67.
51. Berer M. The quinacrine controversy continues. Reprod Health Matters. 6:1995;144.
52. Laufe L.E., Sokal D.C., Cole L.P., Shoupe D., Schenken R.S. Phase I prehysterectomy studies of the transcervical administration of quinacrine pellets. Contraception. 54:1996;186.
53. Sokal D.C., Zipper J., Guzman-Serani R., Aldrich T.E. Cancer risk among women sterilized with transcervical quinacrine hydrochloride pellets, 1977-1991. Fertil Steril. 64(2):1995;333.
54. Kessel E. Quinacrine sterilization: an assessment of risks for ectopic pregnancy, birth defects and cancer. Adv Contracept. 14:1998;88.
55. Kessel E. Quinacrine sterilisation revisited (Commentary). Lancet. 344:1994;698-700.
56. Informed choice and sterilization: special challenges (Insights into Reproductive Health). 1999;AVSC International, New York.
57. Informed choice in international family planning service delivery: strategies for the 21st century (Meeting report). 1999;AVSC International, New York.
58. Cook R.J., Dickens B.M. Voluntary and involuntary sterilization: denials and abuses of rights. Int J Gynecol Obstet. 68(1):2000;61-67.
59. Informed choice in family planning: legacies and challenges (Insights into Reproductive Health). 1998;AVSC International, New York.
60. Achievements in public health, 1900-1999: family planning. Maternal Mortal Wkly Rep 1999;48:47.
61. Sokal D.C., Zipper J., King T. Transcervical quinacrine sterilization: clinical experience. Int J Gynecol Obstet. 51(Suppl 1):1995;S64-S67.
62. Laufe L.E., Sokal D.C., Cole L.P., Shoupe D., Schenken R.S. Phase I prehysterectomy studies of the transcervical administration of Quinacrine pellets. Contraception. 54:1996;186.
63. Sokal D.C., Zipper J., Guzman-Serani R., Aldrich T.E. Cancer risk among women sterilized with transcervical Quinacrine hydrochloride pellets, 1977-1991. Fertil Steril. 64(2):1995;333.
64. Epstein S. Impure science: AIDS, activism and the politics of knowledge. 1996;331-353 University of California Press, Berkeley.
65. Epstein S. Impure science: AIDS, activism and the politics of knowledge. 1996;337-338 University of California Press, Berkeley.
66. Epstein S. Impure science: AIDS, activism and the politics of knowledge. 1996;340-341 University of California Press, Berkeley.
67. Sclove R.E. Democratization and technology. 27:1995;180-181 Guilford Press, New York, London.
68. Contraceptive introduction reconsidered: a review and conceptual framework. 1994;WHO, Geneva.
69. Simmons R., Hall P., Díaz J., Díaz M., Fajans P., Satia J. The strategic approach to contraceptive introduction. Studies Fam Plann. 28(2):1997;79-80.
70. Contraceptive introduction reconsidered: a review and conceptual framework. 1994;6-8 WHO, Geneva.
71. Creating common ground: women's perspectives on the selection and introduction of fertility regulation technologies (Meeting report). 1991;WHO, Geneva.
72. Creating common ground: women's perspectives on the selection and introduction of fertility regulation technologies (Meeting report). 1991;10-40 WHO, Geneva.
73. Declaration of the international symposium on Contraceptive research and development for the year 2000 and beyond (Appendix). Van Look P.F.A., Pérez-Palacios G. Contraceptive research and development 1984-1994: the road from Mexico City to Cairo and beyond. 1994;545-546 Oxford University Press, New Delhi.
74. Day of dialogue on contraceptive methods for today and tomorrow: developments, prospects, and issues. The Population Council, 1994.
75. Winikoff B. New ways to take account of women's perspectives in technology development. Day of dialogue on contraceptive methods for today and tomorrow: developments, prospects, and issues. 1994;17 The Population Council.
76. Cottingham J. Introduction. WHO Beyond acceptability: users' perspectives on contraception. 1997;1-5 Reproductive Health Matters, London.
77. Ellertson C., Winikoff B. Why research on contraceptive user perspectives deserves public sector support: a free-market analysis. WHO Beyond acceptability: users' perspectives on contraception. 1997;16 Reproductive Health Matters, London.
78. Hardon A. Contesting claims on the safety and acceptability of anti-fertility vaccines. Reprod Health Matters. 10:1997;68-80.
79. Harrison P.F., Rosenfield A. Contraceptive research, introduction, and use: lessons from Norplant. 1998;41-45 National Academy Press, Washington, DC.
80. Moshavi S. Late arrival; birth control pill is slow to catch on in Japan. Boston Globe. December 15:1999;WD9.
81. Robotham J. Bad publicity killed good contraceptive, say doctors. Sydney Morning Herald. February 23:1999;4.
82. U.S. trails other countries in birth control advances; sterilization remains favored method here. Baltimore Sun 1999;April 6:5A.
83. Heise L.L. Beyond acceptability: reorienting research on contraceptive choice. WHO Beyond acceptability: users. 1997;11-12 Reproductive Health Matters, perspectives on contraception", London.
84. Programme of Action adopted at the International Conference on Population and Development. 1994;12 United Nations.
85. Creating common ground: women's perspectives on the selection and introduction of fertility regulation technologies (Meeting report). 1991;13 WHO, Geneva.
86. Barroso C. The alliance between feminists and researchers. Van Look P.F.A., Pérez-Palacios G. Contraceptive research and development 1984-1994: the road from Mexico City to Cairo and beyond. 1994;514 Oxford University Press, New Delhi.
87. Fathalla M.F. Fertility control technology: a women-centered approach to research. Sen G., Germain A., Chen L.C. Population policies reconsidered: health, empowerment, and rights. 1994;230 Harvard University Press, Boston.
88. Hardon A. Contesting claims on the safety and acceptability of anti-fertility vaccines. Reprod Health Matters. 10:1997;68-75.
89. Harrison P.F., Rosenfield A. Contraceptive research, introduction, and use: lessons from Norplant. 1998;27 National Academy Press, Washington, DC.